Data presented in this paper provide evidence of the anthelmintic activity and therapeutic effectiveness of 3,3′-diethylthiadicarbocyanine iodide (dithiazanine, Compound 01748) against Strongyloides stercoralis infections in humans and experimental infections with Strongyloides ratti in rats. Prior to this study, a large number of other drugs were evaluated by us for anthelmintic activity against murine and human strongyloidiasis. None of the compounds employed in our previous investigations gave evidence of significant activity or cure of strongyloidiasis in either host. There is a definite need for effective therapeutics for strongyloidiasis. Stoll1 estimated that there were approximately 35,000,000 infections with S. stercoralis in the world. In one hospital in New Orleans in recent years there have been several hundred patients with strongyloidiasis. Jones 2 has described precisely the clinical significance and characteristics of strongyloidiasis. Frequently the infection persists for many years in man, and on rare occasions it may prove fatal.Interpretation
SWARTZWELDER JC, MUHLEISEN JP, ABADIE SH, et al. Therapy of Strongyloidiasis with Dithiazanine. AMA Arch Intern Med. 1958;101(3):658–661. doi:10.1001/archinte.1958.00260150146020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: